Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.64 |
| ▸ | RPA1 | P27694 | 3/20 | 0.63 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | PPP1CA | P62136 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | BCL2 | P10415 | 2/20 | 0.51 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.51 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.51 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.51 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17324802 | 0.89 | NPY5R (0.61) | ALDH1A1MAPK1RPA1NPY5RRIPK1 | |
| SCHEMBL4058019 | 0.86 | SCN9A (0.64) | ALDH1A1MAPK1NPY5RL3MBTL1SCN9A | |
| SCHEMBL21821553 | 0.85 | SMPD1 (0.49) | ALDH1A1MAPK1RPA1NPY5RL3MBTL1 | |
| SCHEMBL2865749 | 0.85 | SMN1; SMN2 (0.66) | ALDH1A1MAPK1RPA1NPY5RL3MBTL1 | |
| SCHEMBL6052304 | 0.85 | KMT2A (0.62) | ALDH1A1MAPK1RPA1NPY5RPPP1CA | |
| SCHEMBL22637874 | 0.84 | MARS1 (0.53) | ALDH1A1MAPK1RPA1NPY5RL3MBTL1 | |
| SCHEMBL20604206 | 0.84 | ALDH1A1 (0.72) | ALDH1A1MAPK1RPA1NPY5RL3MBTL1 | |
| SCHEMBL17321483 | 0.83 | NPY5R (0.56) | ALDH1A1MAPK1RPA1NPY5RBCL2 | |
| SCHEMBL1143854 | 0.81 | RPA1 (0.67) | ALDH1A1RPA1L3MBTL1PPP1CAMEN1 | |
| SCHEMBL21821542 | 0.81 | RPA1 (0.55) | ALDH1A1MAPK1RPA1NPY5RL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6946462-B2 | N-monoacylated derivatives of o-phenylenediamines, their analogs and their use as pharmaceutical agents | HOFFMANN-LA ROCHE INC. (US) | 2005-09-20 | — | — | US | claimed |
| US-6869953-B2 | N-monoacylated derivatives of o-phenylenediamines, their analogs and their use as pharmaceutical agents | HOFFMAN-LA ROCHE INC. (US) | 2005-03-22 | — | — | US | claimed |
| US-20040192744-A1 | N-monoacylated derivatives of o-phenylenediamines, their analogs and their use as pharmaceutical agents | HAAG RAINER (DE) | 2004-09-30 | — | — | US | claimed |
| US-20030139404-A1 | N-monoacylated derivatives of o-phenylenediamines, their analogs and their use as pharmaceutical agents | HOFFMANN-LA ROCHE INC. | 2003-07-24 | — | — | US | claimed |
| US-20260138966-A1 | WNT SIGNALING PATHWAY INHIBITORS FOR TREATMENTS OF DISEASE | UNIV OF MARYLAND BALTIMORE (US) | 2026-05-21 | — | — | US | disclosed |
| US-12378220-B2 | WNT signaling pathway inhibitors for treatments of disease | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2025-08-05 | — | — | US | disclosed |
| EP-3423452-B1 | WNT SIGNALING PATHWAY INHIBITORS FOR TREATMENTS OF DISEASE | UNIV MARYLAND (US) | 2025-05-07 | — | — | EP | disclosed |
| US-20240208927-A1 | WNT SIGNALING PATHWAY INHIBITORS FOR TREATMENTS OF DISEASE | UNIVERSITY OF MARYLAND, BALTIMORE | 2024-06-27 | — | — | US | disclosed |
| US-20240208927-A1 | WNT SIGNALING PATHWAY INHIBITORS FOR TREATMENTS OF DISEASE | UNIVERSITY OF MARYLAND, BALTIMORE | 2024-06-27 | — | — | US | disclosed |
| US-11655233-B2 | WNT signaling pathway inhibitors for treatments of disease | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2023-05-23 | — | — | US | disclosed |
| US-11655233-B2 | WNT signaling pathway inhibitors for treatments of disease | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2023-05-23 | — | — | US | disclosed |
| US-11655233-B2 | WNT signaling pathway inhibitors for treatments of disease | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2023-05-23 | — | — | US | disclosed |
| WO-2005061477-A1 | BIARYL SULFONAMIDES AS MMP INHIBITORS | WYETH (US) | 2005-07-07 | — | — | WO | disclosed |
| US-20050143422-A1 | Biaryl sulfonamides and methods for using same | WYETH (US) | 2005-06-30 | — | — | US | disclosed |
| US-20050130989-A1 | N-arylheteroaromatic products compositions containing them and use thereof | AVENTIS PHARMA S. A. (FR) | 2005-06-16 | — | — | US | disclosed |
| US-6884821-B1 | Carboxylic acid derivatives and drugs containing the same | EISAI CO., LTD. (JP) | 2005-04-26 | — | — | US | disclosed |
| US-6869953-B2 | N-monoacylated derivatives of o-phenylenediamines, their analogs and their use as pharmaceutical agents | HOFFMAN-LA ROCHE INC. (US) | 2005-03-22 | — | — | US | disclosed |
| EP-1435948-A1 | AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | Pharmacia Italia S.p.A. (IT) | 2004-07-14 | — | — | EP | disclosed |
| WO-2003013517-A1 | AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | PHARMACIA ITALIA S.P.A. (IT) | 2003-02-20 | — | — | WO | disclosed |
| EP-1216980-A1 | CARBOXYLIC ACID DERIVATIVES AND DRUGS CONTAINING THE SAME | Eisai Co., Ltd. (JP) | 2002-06-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192744-A1 | N-monoacylated derivatives of o-phenylenediamines, their analogs and their use as pharmaceutical agents | NAT1, CYP1A1, UGT1A1 | ALDH1A1 198/4885MAPK1 808/4885RPA1 3130/4885 |
| US-12378220-B2 | WNT signaling pathway inhibitors for treatments of disease | WNT1, CTNNB1, WNT3A | ALDH1A1 4413/4885MAPK1 141/4885RPA1 3936/4885 |
| US-20050143422-A1 | Biaryl sulfonamides and methods for using same | STS, MMP3, AADAC | ALDH1A1 634/4885MAPK1 4871/4885RPA1 3979/4885 |
| US-20050130989-A1 | N-arylheteroaromatic products compositions containing them and use thereof | AHR, NQO1, ARNT | ALDH1A1 360/4885MAPK1 3623/4885RPA1 4345/4885 |
| US-11655233-B2 | WNT signaling pathway inhibitors for treatments of disease | WNT1, CTNNB1, WNT3A | ALDH1A1 4413/4885MAPK1 141/4885RPA1 3936/4885 |
| US-20260138966-A1 | WNT SIGNALING PATHWAY INHIBITORS FOR TREATMENTS OF DISEASE | CTNNB1, WNT1, CTNND1 | ALDH1A1 3230/4885MAPK1 475/4885RPA1 4546/4885 |
| US-20030139404-A1 | N-monoacylated derivatives of o-phenylenediamines, their analogs and their use as pharmaceutical agents | NAT1, CYP1A1, UGT1A1 | ALDH1A1 198/4885MAPK1 808/4885RPA1 3130/4885 |
| US-20240208927-A1 | WNT SIGNALING PATHWAY INHIBITORS FOR TREATMENTS OF DISEASE | WNT1, CTNNB1, WNT3A | ALDH1A1 4413/4885MAPK1 141/4885RPA1 3936/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.